Editorials

Human papillomavirus infection

BMJ 1996; 312 doi: http://dx.doi.org/10.1136/bmj.312.7030.522 (Published 02 March 1996) Cite this as: BMJ 1996;312:522
  1. Jeffrey F Hines,
  2. Shin-Je Ghim,
  3. A Bennett Jenson
  1. Gynecologic oncologist Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Fort Sam Houston, Texas, USA
  2. Research assistant professor of pathology Professor of pathology Department of Pathology, Georgetown University Medical Center, Washington, District of Columbia, USA

    Pathogenesis suggests new strategies for preventing and treating cervical dysplasia and cancer

    Cervical cancer is estimated to cause 500000 deaths each year worldwide. The public health impact of controlling precursor cervical lesions and cancer is potentially huge, especially in developing countries, where the incidence of cervical cancer approaches 40 per 100000 women.1 Advances in cellular and molecular biology and immunology enable detailed investigation of disease pathogenesis. These advances help our understanding of the role that human papillomaviruses play in premalignant and malignant lesions of the cervix and have important ramifications for the way we diagnose, screen, and treat associated disease. In this issue of the BMJ Lehtinen and colleagues report on a study that directly applied molecular immunology to clinical and epidemiological medicine to support existing scientific evidence of human papillomavirus and its association with invasive cervical …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe